All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.74 [0.67 ; 0.82 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 16 67% 8,963 moderate critical deaths (OS) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.74 [0.64 ; 0.86 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 6 72% 3,817 moderate not evaluable PFS (extension)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.70 [0.57 ; 0.87 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 8 91% 4,699 moderate serious progression or deaths (PFS)detailed results CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.72 [0.61 ; 0.85 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 15 88% 8,217 moderate critical objective responses (ORR)detailed results CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
ORIENT-11, 2020 2.54 [1.63; 3.97]
1.51 [1.17 ; 1.96 ] CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 14 84% 7,676 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.62 [1.11 ; 2.38 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 6 85% 3,817 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.53 [0.27 ; 1.04 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 7 73% 3,843 moderate serious AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.67 [0.43 ; 1.06 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 7 91% 3,843 moderate not evaluable AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
ORIENT-11, 2020 0.31 [0.11; 0.90]
0.95 [0.69 ; 1.30 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 7 0% 3,843 low not evaluable AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.02 [0.59 ; 1.77 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, ORIENT-11, 2020 7 85% 3,843 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.43 [0.89 ; 2.29 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 4 61% 2,283 low not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.07 [0.80 ; 1.44 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 863 moderate not evaluable STRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.66 [0.46 ; 0.94 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 5 55% 2,418 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.73 [0.49 ; 1.08 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020 3 39% 1,555 moderate not evaluable TRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.23 [0.19 ; 0.27 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 6 0% 3,669 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.28 [0.23 ; 0.34 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 6 38% 3,669 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
0.97 [0.56 ; 1.66 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 6 0% 3,697 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.73 [0.57 ; 0.93 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 5 0% 3,120 moderate serious TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.12 [0.82 ; 1.53 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.39 [0.24 ; 8.16 ] KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 3 0% 2,579 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.27 [0.04 ; 1.98 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 3 0% 2,502 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.04 [0.02 ; 0.09 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.02 ; 48.81 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.21 [0.07 ; 0.58 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 3 0% 2,502 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.98 [0.09 ; 10.85 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Colitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
2.96 [0.88 ; 9.97 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 6 0% 4,129 moderate serious Constipation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.78 [0.12 ; 5.15 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.37 [0.16 ; 0.87 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.26 [0.16 ; 9.77 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 3 0% 1,632 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.29 [0.57 ; 2.94 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 6 0% 3,900 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.98 [0.06 ; 15.72 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.41 [0.22 ; 0.79 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
6.10 [1.76 ; 21.13 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 3,825 moderate serious Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.91 [0.21 ; 3.86 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 7 0% 4,526 moderate serious Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.87 [0.33 ; 10.75 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 4 0% 2,883 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.41 [0.40 ; 5.02 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 8 0% 5,056 moderate serious Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.88 [0.47 ; 7.56 ] EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 3 0% 2,345 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.03 [0.87 ; 4.76 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 4 0% 2,875 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.39 [0.09 ; 1.76 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,711 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.05 [0.01 ; 0.38 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.95 [0.18 ; 21.58 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021 2 0% 1,227 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.70 [0.04 ; 11.17 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 2 0% 911 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.12 [0.03 ; 0.47 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
2.16 [0.46 ; 10.05 ] EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 3,580 moderate serious Neutropenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.02 [0.01 ; 0.06 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.65 [0.23 ; 11.94 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.44 [0.06 ; 3.02 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,478 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.08 [0.00 ; 1.43 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.69 [1.09 ; 6.62 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 7 20% 4,526 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.10 [0.19 ; 6.43 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 4 0% 2,899 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.66 [0.05 ; 8.61 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.46 [0.55 ; 3.91 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 6 4% 4,145 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
3.88 [0.61 ; 24.61 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 62% 2,162 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.44 [0.06 ; 3.17 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.05 [0.02 ; 0.17 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.78 [0.08 ; 7.49 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
0.20 [0.05 ; 0.87 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 4 0% 2,806 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-407, 2018 10.24 [0.56; 188.30]
5.05 [0.55 ; 46.09 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
KEYNOTE-407, 2018 0.33 [0.03; 3.22]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.37 [0.07 ; 1.93 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 3 0% 1,976 low not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
KEYNOTE-407, 2018 0.72 [0.46; 1.11]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
0.23 [0.08 ; 0.66 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 92% 3,132 moderate serious Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-407, 2018 2.03 [0.37; 11.17]
1.52 [0.33 ; 6.97 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
KEYNOTE-407, 2018 0.60 [0.21; 1.66]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
0.94 [0.55 ; 1.61 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 11% 3,132 low not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
0.36 [0.05 ; 2.37 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Colitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.04 [0.50 ; 8.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
1.12 [0.41 ; 3.00 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 0% 3,132 low not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
0.89 [0.23 ; 3.46 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 4 0% 2,435 low not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
KEYNOTE-407, 2018 1.21 [0.37; 4.02]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
1.52 [0.71 ; 3.21 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 0% 3,132 low not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
KEYNOTE-407, 2018 1.88 [0.69; 5.16]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
0.83 [0.33 ; 2.14 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 50% 3,132 low serious Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
KEYNOTE-407, 2018 3.04 [0.31; 29.44]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
1.10 [0.62 ; 1.96 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 0% 3,132 low not evaluable Epistaxis AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.02; 50.94]
1.01 [0.02 ; 50.94 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
KEYNOTE-189, 2018 2.37 [0.89; 6.34]
KEYNOTE-407, 2018 0.82 [0.33; 2.01]
MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
1.02 [0.57 ; 1.84 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 28% 3,132 low not evaluable Febrile neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86]
0.05 [0.01 ; 0.41 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Hypertension AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68]
0.48 [0.10 ; 2.29 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Hyperthyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypophysitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 4.05 [0.18; 90.23]
4.05 [0.18 ; 90.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Increase AST AE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74]
EMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
5.45 [1.59 ; 18.72 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3 0% 1,776 moderate not evaluable Increased ALT AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
5.03 [0.87 ; 28.91 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Increased Lipase Level AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results KEYNOTE-407, 2018 4.07 [0.45; 36.67]
4.07 [0.45 ; 36.67 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.50 [0.01 ; 25.20 ] KEYNOTE-189, 2018 1 0% 607 NA not evaluable Leucopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.10 [0.01; 0.83]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05]
0.15 [0.03 ; 0.68 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Myalgia AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.18; 22.43]
2.02 [0.18 ; 22.43 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable myocarditis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nausea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56]
KEYNOTE-189, 2018 1.00 [0.40; 2.51]
KEYNOTE-407, 2018 0.75 [0.17; 3.39]
MYSTIC (D ; all population), 2020 0.16 [0.02; 1.31]
0.50 [0.21 ; 1.16 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 22% 3,132 low serious Neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.05 [0.01; 0.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14]
KEYNOTE-189, 2018 1.39 [0.84; 2.30]
KEYNOTE-407, 2018 0.90 [0.61; 1.32]
MYSTIC (D ; all population), 2020 0.07 [0.02; 0.24]
0.20 [0.06 ; 0.71 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020 5 93% 3,132 moderate serious Pancytopenia (AE grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.47 [0.07 ; 3.32 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-21 08:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563